Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jun;57(6):1426-1436.
doi: 10.1038/s41588-025-02191-5. Epub 2025 Jun 9.

Genetic modifiers of somatic expansion and clinical phenotypes in Huntington's disease highlight shared and tissue-specific effects

Collaborators

Genetic modifiers of somatic expansion and clinical phenotypes in Huntington's disease highlight shared and tissue-specific effects

Genetic Modifiers of Huntington’s Disease (GeM-HD) Consortium. Nat Genet. 2025 Jun.

Abstract

An inherited, expanded CAG repeat in HTT undergoes further somatic expansion to cause Huntington's disease (HD). To gain insights into this molecular mechanism, we compared genome-wide association studies of somatic expansion in blood and somatic expansion-driven HD clinical phenotypes. Here, we show that somatic expansion is driven by a mismatch repair-related process whose genetic modification and consequences show unexpected complexity, including cell-type specificity. The HD clinical trajectory is further modified by non-DNA repair genes that differentially influence measures of cognitive and motor dysfunction. In addition to shared (DNA repair genes MSH3, PMS2 and FAN1) and distinct trans-modifiers, a synonymous CAG-adjacent variant in HTT dramatically hastens motor onset without increasing somatic expansion, while a cis-acting 5'-untranslated region variant promotes blood repeat expansion without influencing clinical HD. Our findings are directly relevant to the therapeutic suppression of expansion in DNA repeat disorders and provide additional clues to HD pathogenic mechanisms beyond somatic expansion.

PubMed Disclaimer

Conflict of interest statement

Competing interests: J.F.G. and V.C.W. were founding scientific advisory board members with a financial interest in Triplet Therapeutics. Their financial interests were reviewed and are managed by Massachusetts General Hospital (MGH) and MGB in accordance with their conflict of interest policies. J.F.G. consults for Transine Therapeutics (dba Harness Therapeutics), has previously provided paid consulting services to Wave Therapeutics USA, Biogen and Pfizer, and receives research funding from Pfizer. V.C.W. is a scientific advisory board member of LoQus23 Therapeutics and has provided paid consulting services to Acadia Pharmaceuticals, Alnylam, Biogen, Passage Bio and Rgenta Therapeutics. V.C.W. and R.M.P. have received research support from Pfizer. J.-M.L. consults for GenKOre and serves on the scientific advisory board of GenEdit. Within the last 36 months, D.G.M. has been a scientific consultant and/or received an honoraria or grants from AMO Pharma, Dyne, F. Hoffman–La Roche, LoQus23, MOMA Therapeutics, Novartis, Ono Pharmaceuticals, Pfizer Pharmaceuticals, Rgenta Therapeutics, Sanofi, Sarepta Therapeutics, Script Biosciences, Triplet Therapeutics and Vertex Pharmaceuticals. D.G.M. also had research contracts with AMO Pharma and Vertex Pharmaceuticals. J.D.L. is a paid Advisory Board member for F. Hoffmann–La Roche and uniQure biopharma and is a paid consultant for Vaccinex, Wave Life Sciences USA, Genentech, Triplet and PTC Therapeutics. T.H.M. is an associate member of the scientific advisory board of LoQus23 Therapeutics and has consulted for Transine Therapeutics (dba Harness Therapeutics). P.H. is a member of the Enroll-HD Scientific Review Committee. S.K. and C.S. are employed by CHDI Management as advisors to the CHDI Foundation. E.R.D. has provided consulting services to Abbott, Abbvie, Acadia, Acorda Therapeutics, Biogen, Biohaven Pharmaceuticals, BioSensics, Boehringer Ingelheim, Caraway Therapeutics, Cerevance, CuraSen, DConsult2, Denali Therapeutics, Eli Lilly, Genentech, Health & Wellness Partners, HMP Education, Karger, KOL groups, Life Sciences Consultant, Mediflix, Medrhythms, Merck, Mitsubishi Tanabe Pharma America, MJH Holdings, NACCME Novartis, Otsuka, Praxis Medicine, Sanofi, Seelos Therapeutics, Spark Therapeutics, Springer Healthcare, Theravance Biopharmaceuticals and WebMD. He has received grant support from Averitas Pharma, Biogen, Burroughs Wellcome Fund, Pfizer, Photopharmics and Roche and has an ownership interest in Included Health, Mediflix, SemCap and Synapticure. G.B.L. has provided consulting services, scientific advice, scientific advisory board functions, independent data monitoring committee services and/or lectures for Acadia Pharmaceuticals, Affiris, Allergan, Alnylam, Amarin, AOP Orphan Pharmaceuticals, Bayer Pharma, Boehringer Ingelheim, CHDI Foundation, Deutsche Huntington-Hilfe, Desitin, Genentech, Genzyme, GlaxoSmithKline, F. Hoffmann–La Roche, Ipsen, ISIS Pharma (IONIS), Lilly, Lundbeck, Medesis, Medivation, Medtronic, NeuraMetrix, Neurosearch, Novartis, Pfizer, Prana Biotechnology, Prilenia, PTC Therapeutics, Raptor, Remix Therapeutics, Rhône-Poulenc Rorer, Roche Pharma AG Deutschland, Sage Therapeutics, Sanofi-Aventis, Sangamo/Shire, Siena Biotech, Takeda, Temmler Pharma GmbH, Teva, Triplet Therapeutics, Trophos, UniQure and Wave Life Sciences. R.H.M. is a paid advisory board member for Rgenta Therapeutics and is on the scientific advisory board with financial interests in Gatehouse Bio. All other authors declare no competing interests.

Update of

References

    1. Huntington’s Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington’s disease chromosomes. Cell 72, 971–983 (1993). - DOI
    1. Genetic Modifiers of Huntington’s Disease Consortium. CAG repeat not polyglutamine length determines timing of Huntington’s disease onset. Cell 178, 887–900.e14 (2019). - DOI
    1. Wright, G. E. B. et al. Length of uninterrupted CAG, independent of polyglutamine size, results in increased somatic instability, hastening onset of Huntington disease. Am. J. Hum. Genet. 104, 1116–1126 (2019). - PubMed - PMC - DOI
    1. Ciosi, M. et al. A genetic association study of glutamine-encoding DNA sequence structures, somatic CAG expansion, and DNA repair gene variants, with Huntington disease clinical outcomes. EBioMedicine 48, 568–580 (2019). - PubMed - PMC - DOI
    1. Genetic Modifiers of Huntington’s Disease Consortium. Identification of genetic factors that modify clinical onset of Huntington’s disease. Cell 162, 516–526 (2015). - DOI

MeSH terms

LinkOut - more resources